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Recent polymerase chain reaction data have shown that
most human papillomavirus (HPV) genotypes associated
with epidermodysplasia verruciformis (EV) are wide-
spread; however, HPV5 associated with EV skin carcin-
omas has only rarely been detected in non-EV patients.
To identify the reservoir of this virus, we examined 335
sera from different groups of patients for the presence of
HPV5 antibodies by an enzyme-linked immunosorbent
assay test based on HPV5 virus-like particles. The preval-
ence of antibodies reacting with HPV5 virus-like particles
was found to be significantly higher in psoriatic patients
(24.5%) than in other groups (2–5%), including patients
with atopic dermatitis and renal transplant recipients.
Analysis of scrapings of lesional and uninvolved skin
by a nested polymerase chain reaction method, using
degenerate EV HPV primers, disclosed HPV DNA in
91.7% of 48 psoriatic skin samples and 35.5% of 31 atopic
Epidermodysplasia verruciformis (EV) is a rare geneticdisease characterized by an abnormal susceptibility to aspecific group of related human papillomavirus (HPV)types and the frequent occurrence of cutaneous malignanc-ies mainly associated with HPV5 (Orth, 1987; Majewski
and Jablonska, 1995). EV HPV DNA sequences have only rarely
been detected by molecular hybridization experiments in cutaneous
premalignant tumors and skin cancers in the general population
(Kawashima et al, 1990); however, recent studies using highly sensitive
nested polymerase chain reaction (PCR) have disclosed the presence
of DNA sequences of EV HPV or related HPV types in nonmelanoma
skin tumors of immunosuppressed and immunocompetent individuals
(Berkhout et al, 1995; Pfister and ter Schegget, 1997). EV HPV DNA
sequences have also been found highly prevalent in plucked hairs from
renal transplant recipients (RTR) and healthy volunteers (Boxman
et al, 1997). This indicates that EV HPV cause widespread latent
infections; however, their role in skin carcinogenesis in non-EV patients
remains to be substantiated. Strikingly, using the same approach, HPV5
has only occasionally been detected in skin tumors of non-EV patients
(Berkhout et al, 1995; Shamanin et al, 1996; Pfister and ter Schegget,
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dermatitis specimens. Eleven EV HPV genotypes, most
frequently HPV5 and HPV36, and a putative novel geno-
type (PsoX1) were identified in psoriasis. Five EV HPV
genotypes and two putative novel genotypes (ADX1 and
ADX2) were detected in atopic dermatitis patients. HPV5
was not found in atopic dermatitis patients. Using type
specific primers, HPV5, HPV36, and HPV1 were found
in 89.4%, 84.2%, and 42.1% of specimens from psoriatic
patients, whereas HPV36 was detected in 22.5% of speci-
mens from atopic dermatitis patients. HPV16 was never
detected. On the whole, 27 HPV5 and 13 HPV36 DNA
variants were disclosed after sequencing amplification
products. Our data confirm that EV HPV are widespread
and point to psoriasis as a reservoir for HPV5. Whether
HPV5 is involved in the pathogenesis of psoriasis remains
to be determined. Key words: HPV variants/humoral
response/nested PCR/virus-like particle. J Invest Dermatol
110:311–317, 1998
1997) and in plucked hairs (Boxman et al, 1997). This raises the
question of the reservoir for HPV5.
Therefore, our first aim was to search for antibodies to HPV5 in
patients with common cutaneous disorders [psoriasis and atopic derma-
titis (AD)], in RTR (a population at risk for the development of skin
neoplasia), in patients with anal warts, and in subjects with no known
history of HPV infection. We disclosed a significant prevalence of anti-
HPV5 antibodies only in patients with psoriasis. Psoriasis is characterized
by an epidermal proliferation (Christophers and Sterry, 1993), which
appears to be a secondary event related to activation of T lymphocytes
and production of proinflammatory cytokines and growth factors
(Griffiths and Voorhees, 1996). To find out whether this inflammatory
hyperproliferative epidermal process could permit HPV5 DNA replica-
tion and favor an immune humoral response, we screened for the
presence of HPV5 and other EV HPV in scrapings of lesional and/or
uninvolved skin in psoriatic patients and, as control, in patients with
AD, using a nested PCR technique (Berkhout et al, 1995). Our data
disclosed the presence of HPV5 DNA in most patients with psoriasis
but not in AD patients.
MATERIALS AND METHODS
Clinical samples Sera were obtained from 155 Polish psoriatic patients (62
females and 93 males, mean age 49.2 6 17.9 y). The series studied consisted
of 129 patients with plaque psoriasis, 18 with guttate psoriasis, five with psoriatic
erythroderma, and three with pustular psoriasis. Onset of the disease, its
duration, extent, and activity of lesions, persistence of the last relapse, and
previous treatments were recorded. Sera were also obtained from 44 Polish
patients with AD (mean age 29.7 6 12.1 y) and 14 Polish patients with EV
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(mean age 39.7 6 17.1 y). Southern blot hybridization experiments had shown
that 10 of the EV patients were infected with HPV5, one was infected with
HPV12, and three were infected with HPV3, including the sister of an HPV5
infected patient. All but one of the HPV5 infected patients were found to
harbor at least another EV HPV genotype (Orth G, and Jablonska S, unpublished
results). Sera from 38 Polish RTR (mean age 40.8 6 11.9 y), 38 French
patients with anal condylomata acuminata induced by HPV6 or HPV11 (mean
age 30.1 6 8.4 y), and 60 French individuals with no known history of HPV
infection (mean age 36.1 6 23.5 y) were retrieved from three serum collections.
Scrapings were taken from a single lesion at various anatomical sites (hand,
forearm, back, thorax, groin, leg) of Polish patients with plaque psoriasis (28
cases), guttate psoriasis (nine cases), and AD (16 cases). Scrapings were collected
from two lesions in four patients with plaque psoriasis and one patient with
guttate psoriasis and from noninvolved skin of six patients with plaque psoriasis.
Scrapings were also taken from uninvolved and lesional skin of 12 Polish
patients with AD and from uninvolved or lesional skin of three and four
additional Polish patients, respectively.
Enyme-linked immunosorbent assay (ELISA) test Recombinant baculo-
viruses expressing the L1 capsid protein of HPV5 variants E10 (subtype a), E11
(subtype c), and E5 (a subtype b1 variant) (Kawase et al, 1996) were constructed
and expressed in Sf9 cells. Culture media were collected 72 h after infection
and clarified by low speed centrifugation. After ultracentrifugation of the
supernatants at 100,000 3 g, pellets were resuspended in phosphate buffered
saline and L1 proteins were purified by equilibrium centrifugation in CsCl
gradients. When observed under an electron microscope, purified L1 prepara-
tions contained mostly well assembled virus-like particles (VLP) (Kawase M,
Orth G, and Favre M, in preparation). HPV1 virions were purified from pooled
plantar warts as described previously (Favre et al, 1975). Wells of microplates
(Nunc-immuno module maxisorp F16, Inter Med, Roskilde, Denmark) were
coated with VLP or HPV1 virions (0.1 µg) and sera were tested at a 1/100
dilution (Kirnbauer et al, 1994). To determine the nonspecific reactivity of sera,
each serum was tested in duplicate in wells without antigen. After incubation
for 2 h at 37°C, goat anti-human IgG conjugated to horseradish peroxidase
(Biosys, Compie`gne, France) were used as described by the supplier. The plates
were developed with ortho-phenylene-diamine (0.4 mg per ml) in 0.1 M
citrate buffer (pH 4.0) in the presence of 0.01% hydrogen peroxyde. The
A490 nm values were recorded on a microplaque reader (Metertech S 960).
For each serum, the mean value obtained with buffer coated wells was subtracted
from the mean value of wells coated with each antigen. To score antibody
positive and antibody negative sera, the mean and the SD were calculated for
the 60 sera obtained from subjects with no known history of HPV infection
and a cut-off value (mean 1 3 SD) was deduced after exclusion of outliers
(Mu¨ller et al, 1995). In each experiment, 20 of the negative control sera were
included as standards. The proportions of positive HPV5 or HPV1 sera between
the different groups tested were compared using the Yates’ corrected chi square
test. Tests were considered significant at the p 5 0.05 level.
PCR analysis Total cellular DNA was extracted from scrapings as previously
described (Kawase et al, 1996). The adequacy of DNA preparations was tested
by PCR using β globin primers (Greer et al, 1991). EV associated HPV were
detected by a nested PCR method (Berkhout et al, 1995) with two sets of
degenerate primers (CP65/70 and CP66/69) located in the L1 open reading
frame. To detect specific HPV types, a nested PCR was also performed using
primers located in the L1 open reading frame of HPV1 (1 L1), HPV5 (5 L1),
HPV16 (16 L1), and HPV36 (36 L1). The nucleotide (nt) positions of the two
pairs of primers (1 and 2; 3 and 4) are for 1 L1, nt 5542–5561 and 6137–6156;
nt 5593–5612 and 6066–6085, for 5 L1, nt 5913–5932 and 7015–7034; nt
6124–6143 and 6563–6582, for 16 L1, nt 5909–5928 and 6477–6492; nt 5981–
6000 and 6350–6369, and for 36 L1, nt 6005–6024 and 6602–6621; nt 6098–
6117 and 6537–6556 (Myers et al, 1995). PCR reaction mixtures contained
0.5–1 µg total cellular DNA, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 100 mM
each deoxynucleotide triphosphate, 2.5 mM MgCl2, 25 pM of each primer of
the first pair (primers 1 and 2), and 2 units of Thermus aquaticus DNA
polymerase (Perkin-Elmer, Emeryville, CA). Mixtures were incubated for 5 min
at 95°C for DNA denaturation and 35 cycles of amplification were performed
with a PCR processor (Perkin-Elmer Cetus 9600) (Berkhout et al, 1995). Every
eight PCR reactions, a tube containing water instead of DNA was included as
negative control. Cloned HPV1, 5, 16, and 36 DNA (1 ng) were used as
positive controls. Subsequently, 5 µl of the first PCR were amplified with the
second set of primers (primers 3 and 4). PCR products were submitted to agarose
gel electrophoresis, stained with ethidium bromide to visualize amplimers, alkali
denatured and transferred onto Hybond N1 membranes (Amersham, Les Ulis,
France), and hybridized with random primed 32P-labeled probes. Probes
corresponded to PCR products generated on cloned HPV1, 5, 16, and 36
DNA using the second set of primers. Hybridizations were performed in
nonstringent conditions with an HPV5 DNA probe for the detection of EV
Table I. Seropositivity to HPV5 L1 VLP and HPV1 virions
among different groups of patients and among controlsa
Number (%) of positive sera to
Test group HPV5 HPV1 HPV1 1 5
EV (n 5 14) 10 (71.4) 4 (28.6) 3 (21.4)
Psoriasis (n 5 155) 38 (24.5) 42 (27.1) 12 (7.7)
AD (n 5 44) 2 (4.5) 14 (31.8) 1 (2.3)
RTR (n 5 38) 1 (2.6) 13 (34.2) 1 (2.6)
Genital warts (n 5 38) 1 (2.6) 10 (26.3) 0
Controls (n 5 60) 3 (5.0) 13 (21.7) 1 (1.7)
aAs determined by an ELISA test as described in Materials and Methods.
HPV DNA sequences or in stringent conditions with the homologous probe
for the detection of specific HPV types, as previously described (Kawashima
et al, 1990).
DNA sequence analysis Direct sequencing was performed using the ABI
prism dye terminator cycle sequencing core kit with the ampliTaq FS DNA
polymerase (Perkin-Elmer, Roissy, France) as recommended by the supplier.
Sequence products were analyzed with an ABI Prism 377 DNA sequencer
(Perkin-Elmer). All sequences were compared with the available sequences in
the EMBL/GenBank Databank using the FASTA program. Multiple alignments
of partial HPV5 and HPV36 L1 sequences were performed with the CLUSTAL
W program, and phylogenetic trees were constructed by using the maximum
parsimony or the maximum likelihood methods with the PHYLIP 3.4 programs
(Phylogeny Inference Package) as previously described (Kawase et al, 1996).
Nucleotide sequence accession numbers Sequences have been deposited
at EMBL database under accession numbers Z93786 for EV HPV variant
PsoX1, Z93787 to Z93796 for HPV36 variants P36–1 to P36–10, Z93797 to
Z93815 for HPV5 variants P5–4 to P5–22, AJ001483 and AJ001484 for EV
HPV variants ADX1 and ADX2, and AJ001628 and AJ001629 for HPV36
variants AD 36–2 and AD 36–3.
RESULTS
Anti-HPV5 antibodies in patients with psoriasis Anti-HPV5
antibodies were searched for in different groups of patients by an ELISA
test using purified HPV5 L1 VLP preparations. VLP corresponded to
the most divergent HPV5a and c variants (E10 and E11) and to a
subtype b1 variant (E5), with a nine amino acid insert in the L1
protein (Kawase et al, 1996). Our previous studies had shown that
hyperimmune rabbit anti-sera raised against each of the VLP species
yielded 4- to 16-fold lower ELISA titres when tested on heterologous
VLP and did not cross-react with HPV1 virions. Furthermore, some
of the monoclonal antibodies prepared against HPV5b1 VLP were
found to cross-react with either HPV5a or HPV5c intact VLP. These
distinct antigenic properties disclosed the existence of three HPV5
serotypes (Kawase M, Orth G, and Favre M, in preparation). As
control, we screened for anti-HPV1 antibodies using HPV1 virions.
Antibodies reacting with two or three HPV5 VLP species, i.e., bi-
or trispecific, were detected in 71.4% of 14 EV patients (Tables I and
II, Fig 1). Only the 10 HPV5 infected patients were found seropositive.
Antibodies reacting with at least one preparation of HPV5 VLP were
detected in 38 (24.5%) of 155 psoriatic patients (Table I, Fig 1) and
the majority of these antibodies were monospecific (Table I). This
prevalence was found to be significantly higher than that (2–5%)
observed in the other groups tested, including patients with AD and
RTR (p 5 0.004). In contrast, no significant difference was observed
in the prevalence of anti-HPV1 antibodies (21.7% to 34.2%) in the
different groups, including the EV patients (Table I, Fig 1). Further-
more, no difference in the prevalence of anti-HPV1 antibodies was
observed among HPV5 seropositive and HPV5 seronegative patients
(31.5% and 25.6%, respectively), indicating that the ELISA test is
reliable enough to discriminate between distantly related HPV types.
No correlation was observed between the detection rate of anti-
HPV5 antibodies and the clinical type of psoriasis (plaque and guttate
psoriasis), the age at onset, the duration of the disease, the nature of
treatments (previous PUVA therapy, retinoids, methotrexate), and the
patients’ age; however, the detection rate was significantly higher
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Figure 1. Seroreactivity to HPV5 VLP and HPV1 virions. Sera from 155
psoriatic patients, 60 control subjects, 38 patients with anal warts, 38 RTR, 44
patients with AD, and 14 patients with EV were tested by an ELISA test using
VLP specific for HPV5a, b1, or c and HPV1 virions as described in Materials
and Methods. The cut-off values are indicated by an horizontal line.
Table II. Subtype specificity of patients antibodies to
HPV5 L1 VLPa
Number of sera
Reactivity against Reactive to HPV5 VLP
HPV5a, b1, and c HPV5
Test group VLP positive a b1 c
Psoriasis monospecific 22 8 10 4
(n 5 155) bispecific 7 6 5 3
trispecific 9 9 9 9
total 38 23 24 16
EV monospecific 0 0 0 0
(n 5 14) bispecific 5 3 3 4
trispecific 5 5 5 5
total 10 8 8 9
aAs determined by an ELISA test as described in Materials and Methods.
(43.2%) for 37 patients with lesions covering more than 50% of body
surface than for 65 and 53 patients with lesions covering 20–50%
(15.4%, p 5 0.004) or less than 20% (22.6%, p 5 0.05) of body
surface, respectively.
High prevalence of EV HPV in psoriasis Scrapings of lesional or
uninvolved skin of 37 patients with psoriasis and, as controls, of 19
patients with AD were analyzed for the presence of HPV5 and EV
HPV DNA by a nested PCR method using degenerate consensus
primers designed to detect EV HPV types (Table III) (Berkhout et al,
1995). Among these patients, 10 psoriatic and two AD patients had
detectable anti-HPV5 antibodies. All DNA preparations were negative
after the first round of PCR (primers CP65 and 70), even when PCR
products were analyzed by blot hybridization (data not shown). In
contrast, after the second round of PCR (primers CP66 and 69), a
high proportion of DNA preparations obtained from plaque (93.8%)
and guttate (80%) psoriasis and all six preparations extracted from
uninvolved skin of some of these patients yielded a fragment with the
expected size of about 460 bp (Table III). This fragment was detectable
on ethidium bromide stained agarose gels and after hybridization with
an HPV5 L1 probe under nonstringent conditions. A lower proportion
of preparations obtained from lesional (31.2%) and uninvolved (40%)
skin from AD patients were HPV positive. After direct sequencing of
the PCR products, 10 known EV HPV genotypes were identified in
psoriasis and five in AD patients (Table III). The most prevalent
genotypes were HPV5, HPV36, HPV20, and HPV38 in psoriasis and
HPV24 and HPV38 in AD. In addition, four novel putative EV related
genotypes were detected, two in psoriatic patients, the recently
identified HPV12 related RTRX7 isolate (Ho¨pfl et al, 1997) and an
as yet unrecognized strain (PsoX1) related to HPV17 (73.4% identical
nucleotides among the 354 sequenced), and two isolates in AD patients,
sharing 81.4% and 73.4% sequence homology with HPV17 (ADX1)
Figure 2. Detection of HPV DNA sequences in psoriasis. DNA from
lesional (lanes 2–12, 14–17, and 19) and uninvolved (lanes 13, 18, and 20) skin
of 16 patients were analyzed by nested PCR using primers specific for HPV
types 5, 36, 1, and 16. Positive controls (lane 1) corresponded to cloned HPV
DNA and negative control to human placenta DNA (lane 21). Amplification
products obtained after the first (primers 1 and 2) and second (primers 3 and
4) rounds of PCR were analyzed by blot hybridization as described in Materials
and Methods.
and HPV9 (ADX2), respectively. A double infection was found for
three of 26 psoriatic patients with only one lesional skin specimen
analyzed (HPV5 1 HPV36 or 38, HPV9 1 HPV36) and, for patients
with two specimens tested, six of 11 psoriatic patients (HPV5 1 HPV36,
twice, HPV20 1 HPV38 or RTRX7, HPV36 1 HPV38, and
HPV37 1 HPV38) and one of 12 AD patients (HPV15 1 HPV21).
Strikingly, whereas nine (24.3%) of the 37 psoriatic patients were found
infected with HPV5, none of the 19 patients with AD (31 specimens)
were positive for HPV5.
HPV5 DNA in most psoriatic patients but not in AD Because
nested PCR using type specific primers should be more sensitive to
detect individual HPV types, HPV5 DNA sequences were searched
for in all DNA preparations by nested PCR using HPV5 L1 primers
(Table III). The second pair of primers amplified the 419 bp fragment
taken as a reference for the recognition of three HPV5 subtypes and
25 HPV5 variants in EV patients (Kawase et al, 1996). All DNA
preparations were negative after the first round of PCR (Fig 2). In
contrast, HPV5 was disclosed in 34 (91.9%) of the 37 psoriatic patients
(89.6% of 48 DNA preparations). Five of the six specimens from
uninvolved skin contained HPV5. In contrast, none of the 31 DNA
preparations obtained from AD patients were HPV5 positive
(Table III).
Twenty-seven HPV5 DNA variants were identified after sequencing
(Table III; for accession numbers see Materials and Methods). When
the nucleotide sequences of these variants were aligned with those of
the 25 variants characterized in EV patients, three (P5–1 to P5–3)
were shown to correspond to the already known J1, E3, and E10
variants (Kawase et al, 1996) (Fig 3). Six variants (P5–1, 22, 28,
213, 216, and 217) were found in several (2–5) patients. Four
patients were found infected with two variants. Thirty-one (7.4%) of the
419 nucleotide positions were found variable and pairwise comparison
revealed nucleotide substitution rates ranging from 0.2% (a single
mutation) to 4.5% (19 mutations for P5–1 and P5–19 variants). A
phylogenetic analysis of the HPV5 DNA variants allowed distribution
of 25 psoriasis variants into subtype a and of two variants into subtype
b (Fig 3A). None of the two HPV5b variants contained the 27
nucleotide/nine amino acid insert (Kawase et al, 1996). Nonsynonym-
ous mutations affected six (4.3%) of the 139 residues of the deduced
amino acid sequence and eight polypeptide variants were disclosed that
differed by one or two amino acid substitutions. All protein variants
were clustered in the group including EV HPV5a DNA variants and
EV HPV5b variants lacking the insert (Fig 3B).
Frequent multiple HPV infection in psoriasis The high preval-
ence of HPV5 infection found with type specific primers clearly
demonstrated that degenerate primers underestimate the prevalence of
individual EV HPV types and the occurrence of multiple infections.
Furthermore, the primers used were reported to amplify the mucosal
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Figure 3. Phylogenetic trees of HPV5 and HPV36 variants. (A) Sequences
of a 419-nucleotide L1 fragment of the 27 HPV5 (P5–1 to P5–27) found in
psoriasis and 13 HPV36 variants found in psoriatic (P36–1 to P36–10) and AD
(AD36–1 to AD 36–3) patients were aligned with those of 25 HPV5 variants
previously found in patients with EV (Kawase et al, 1996) and of the prototype
HPV36 (36EV) (Myers et al, 1995). A phylogenetic tree was constructed by
using the maximum likelihood method. HPV5 and HPV36 isolates identified
in this study are boxed. Sequences have been deposited at EMBL database
under the accession numbers given in Material and Methods. (B) Tree constructed
from the alignment of the deduced 139 amino acid sequences of HPV5 L1
variants. The EV isolates (E5, E10, and E11) corresponding to the L1 VLP
used in ELISA tests are underlined.
HPV and the cutaneous HPV1 (Berkhout et al, 1995) but detected
only EV HPV in our study. This prompted us to further analyze 19
HPV5 positive DNA preparations obtained from 12 patients with
plaque psoriasis and four patients with guttate psoriasis and all DNA
preparations obtained from AD patients by a nested PCR using primers
specific for HPV36, an EV HPV (Kawashima et al, 1990) as frequently
detected as HPV5 in psoriasis using degenerate primers, and for two
genotypes distantly related to EV HPV, HPV1 associated with plantar
warts, and HPV16 associated with cervical cancer (Table III). The
second pair of primers amplified the same L1 region as for HPV5.
HPV36 DNA sequences were disclosed in 16 (84.2%) and seven
(22.6%) DNA preparations obtained from psoriasis and AD patients,
respectively (Table III, Fig 2). Sequencing of PCR products (419 bp)
revealed 12 variable nucleotide positions as compared with the proto-
type HPV36 (Myers et al, 1995). This led to the recognition of 13
HPV36 variants, 10 in psoriasis (P36–1 to 210) and three in AD
(AD36–1 to 23) (Table III; for accession numbers see Materials and
Methods). Some variants (P36–1, 24, and 26, AD 36–3) were identified
several times and one variant was found both in psoriasis (P36–4) and
AD (AD36–1). Two psoriasis patients were found to be infected with
two variants. All these variants were clustered in a single phylogenetic
group (Fig 3A).
HPV1 DNA sequences were detected in eight (42.1%) DNA
preparations obtained from psoriatic lesions but not in AD patients.
Only one of the eight sequenced HPV1 PCR products differed from
the prototype, showing an A5793→C substitution already described
Table IV. HPV genotypes found in HPV5 seropositive
patients
HPV5 subtype specificity of
antibodiesb
Case HPV genotypesa a b1 c
EV
1 5a (E1),3,22,36,49 1 1
2 5a (E3),9 1 1
3 5a (E3),3 1 1
4 5a (E3),3,8,9,14,17,19,20,22,24,36 1 1 1
5 5a (E3),3,8,19,24,36 1 1 1
6 5a (E9),20 1 1 1
7 5,36 1 1 1
8 5a (E8),3,21,23 1 1 1
9 5a (E9),8,20,23,36 1 1
10 5b1 (E5),3,8,9,17,19,22,36 1 1
Psoriasis
1 5a (P5–20),1,20,36 (P36–6, 27) 1 1
2 5a (P5–6),9,36 1 1 1
3 5a (P5–2, 225),36 1 1 1
4 5a (P5–1),38 1
5 5a (P5–13),36 1
6 5a (P5–21),20 1
7 5a (P5–23),15,36 (P36–10) 1
8 5a (P5–12),36 (P36–2) 1
9 5a (P5–18),37 1
10 5a (P5–11),1,36 (P36–4),PsoX1 1
aAs determined by Southern blot experiments (EV cases) or nested PCR and sequencing
(psoriasis cases). HPV5 subtypes and HPV5 and 36 variants (in parentheses) were identified
by sequencing the PCR products from lesions of EV (Kawase et al, 1996) and psoriasis
(this study).
bAs determined by an ELISA test as described in Materials and Methods.
(Myers et al, 1995). In contrast, HPV16 DNA sequences were not
detected in any of the psoriasis and AD patients (Table III).
HPV5 subtype specificity of antibodies and EV HPV genotypes
detected in patients Of the EV patients found seropositive, eight
had been found infected with an HPV5a variant and one with an
HPV5b1 variant (Kawase et al, 1996). All but one positive sera reacted
with the homologous VLP (Table IV). All sera also reacted with one
or two other HPV5 VLP species, as expected from the partial cross-
reactions observed among the three HPV5 L1 proteins (Kawase M,
Orth G, and Favre M, in preparation). Because most patients were
also infected with at least another EV HPV genotype (Table IV),
cross-reactions between HPV5 and closely related EV HPV genotypes,
such as HPV36, have also to be considered.
Among the 155 patients with psoriasis, antibodies to HPV5 VLP
were found in 10 (27.1%) patients of the subset of 37 analyzed for the
presence of HPV DNA sequences. No correlation could be observed
between the viral load and seroconversion because a nested PCR was
required in all cases to detect HPV5 and only one of the 10 seropositive
patients was found infected with HPV5 using the less sensitive consensus
primer approach. All seropositive patients were infected with HPV5a
variants but only three reacted with HPV5a VLP. All were infected
with one or two other EV HPV genotypes (Table IV). Antibodies
were detected in 28 (23.7%) of the 118 patients for whom no
information was available on HPV status. Antibodies to HPV5a VLP
were found in 20 (71.4%) of the 28 seropositive patients, in agreement
with the very high prevalence of HPV5a variants in the 37 patients.
DISCUSSION
Our data point to a frequent infection of psoriatic patients with EV
HPV, especially with HPV5. This virus is associated to EV carcinomas
and its reservoir has long been searched for (Orth, 1987). The results
of this study suggest that the high prevalence of HPV5 infection in
psoriasis is characteristic of this disease.
Our conclusions are based on (i) the presence of antibodies reacting
against HPV5 VLP in a significant proportion of psoriatic patients,
especially in patients with extensive skin involvement, as compared
with the low prevalence in other study groups; (ii) the detection of
HPV5 and some other EV HPV genotypes by nested PCR in lesional
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and uninvolved skin of over 90% of psoriatic patients; and (iii) the
lack of detection of HPV5 DNA sequences and the low prevalence of
antibodies reacting against HPV5 VLP in AD patients. Similarly, HPV5
had not been detected previously by nested PCR in precancers
and nonmelanoma carcinomas of the skin of immunosuppressed or
immunocompetent patients (Berkhout et al, 1995; Shamanin et al,
1996; Pfister and ter Schegget, 1997) and had seldom been found in
plucked hairs (Boxman et al, 1997).
Several aspects of the virologic data deserve to be stressed. (i) Eleven
and five already known EV HPV genotypes were detected in psoriasis
and AD patients, respectively, and three novel EV HPV related
genotypes (PsoX1, ADX1, ADX2) were identified. This further
confirms that the amazing plurality recognized for EV HPV (Orth,
1987) is much greater than anticipated (Berkhout et al, 1995; Boxman
et al, 1997; Pfister and ter Schegget, 1997). (ii) The HPV5 isolates
found in psoriasis showed a great genetic heterogeneity similar to that
previously disclosed in EV patients (Kawase et al, 1996). Twenty-four
of the 27 HPV5 variants identified in psoriasis had not been detected
previously in EV patients. Furthermore, 13 HPV36 variants were also
characterized, indicating that a great intratype heterogeneity is a
common feature to EV HPV. (iii) About 25% of psoriatic patients
were found infected with more than one EV HPV type using degenerate
PCR primers and many more patients using primers specific for HPV5
or HPV36. Similarly, HPV1, a distantly related genotype associated
with plantar warts, was identified in a proportion of patients using
type specific primers. It may thus be assumed that more EV HPV
genotypes or other cutaneous or genital genotypes could have been
detected with the same approach; however, none of the patients
screened for HPV16 were found positive, as could have been expected
from previous reports on the detection of this oncogenic genital
genotype in single cases of precancers and nonmelanoma carcinomas
of the skin developing after PUVA therapy in psoriatic patients
(Weinstock et al, 1995; Ru¨bben et al, 1996). (iv) It should be stressed
that the amounts of viral DNA molecules detected in the specimens
were very small because we had to use a very sensitive two-step nested
PCR method. The detection level of the DNA of most EV HPV has
been estimated to 1 fg (100 viral DNA molecules) using degenerate
primers (Berkhout et al, 1995) and 50 DNA molecules for HPV5 by
using type specific primers (M Favre, unpublished results).
Evidence for a humoral response against HPV5 in psoriatic patients
was obtained using an ELISA test with VLP specific for the three
HPV5 serotypes previously characterized (Kawase M, Orth G, Favre
M, in preparation). Several data support the hypothesis that the
serologic assay used is specific: (i) no correlation was observed between
the seropositivity detected with HPV5 VLP and that detected with
HPV1 virions; (ii) the detection of anti-HPV5 antibodies in EV patients
was restricted to the patients infected with HPV5; (iii) all positive sera
of EV patients reacted with two or three HPV5 VLP species, in
agreement with the partial cross-reactions observed between the
HPV5 serotypes; and (iv) antibodies reacted with the VLP species
corresponding to the subtype infecting the patients in all but one case.
In contrast to EV patients, antibodies were detected only in a part
of HPV5 infected psoriatic patients. Furthermore, although HPV5a is
likely to be present in almost all psoriatic patients, antibodies reacting
with this subtype were only detected in 60% of the seropositive
patients. Moreover, 58% of the sera reacted only with a single HPV5
VLP species. Several explanations may be proposed: (i) the prevalence
of antibodies is likely to be related to the low level of virus production;
(ii) low HPV5a antibody titres could account for an apparent lack of
cross-reaction with other VLP species; (iii) it cannot be excluded that
some HPV5a variants, such as P5–4, 26, 28, and 211 (Fig 3B),
cross-react only partially with the E10 isolate used for the preparation
of HPV5a VLP; (iv) more extensive screening of the patients could
have disclosed additional HPV5 variants; (v) antibodies restricted to
HPV5b1 or HPV5c VLP could reflect past infections with these
variants or result from cross-reactions with other EV HPV genotypes
present in the patient.
The high prevalence of HPV5 in psoriasis, contrasting with the
absence of this virus in AD, suggest that some factors involved in the
epidermal hyperproliferation in psoriasis may facilitate the replication
of viral DNA. Because heritable genetic factors are involved in both
EV (Orth, 1987; Majewski and Jablonska, 1995) and psoriasis (Ho¨hler
et al, 1997; Nair et al, 1997), it could be speculated that psoriatic
patients have a genetically determined predisposition to persistent
HPV5 infection. It is well established that productive HPV DNA
replication and capsid gene expression take place only in terminally
differentiating keratinocytes (Orth, 1987). In psoriasis, this terminal
differentiation is markedly altered, due to the highly increased ker-
atinocyte turnover. This, as well as the steady desquamation of the
stratum corneum, could account for a very low yield of HPV DNA
in scrapings; however, the presence of antibodies against HPV5 VLP
in sera of psoriatic patients indicates that viral capsid proteins or virions
are produced in psoriatic skin in sufficient amounts to allow recognition
by the immune system. Although several microbial proteins or superan-
tigens (Valdimarsson et al, 1995) have been suspected to be responsible
for T cell activation, no specific T cell clones have been detected
(Prens et al, 1991). The results of T cell receptor studies are controversial
(Chang et al, 1994; Boehncke et al, 1995; Moss et al, 1997; Norris
et al, 1997; Vekony et al, 1997). Mono or oligoclonality of T cells
demonstrated in repeated biopsies from lesional skin of psoriasis suggests
their recruitment in situ and a classical pathway of antigen activation,
possibly by infectious agents that cross-react with a normal epidermal
protein (Chang et al, 1994). Moreover, psoriatic keratinocytes express
major histocompatibility complex class II molecules and therefore
could be actively involved in antigen presentation (Prens et al, 1991).
It is conceivable that the L1 protein of HPV5 or other HPV types
present in the stratum corneum might be the antigen stimulating T
cell dependent antibody production.
In conclusion, the detection of antibodies against HPV5 in a
proportion of psoriatic patients and the presence of HPV5 DNA
sequences in the great majority of such patients strongly suggest that
psoriasis is a reservoir for this virus. The pathogenic significance of the
very high prevalence of HPV5 variants in psoriasis remains to be
established.
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